BusinesspSivida’s Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 StudyBy Nasdaq OMXJun 13, 2017, 11:00 AM UTC
